The elevated serum FGF19 was previously showed in patients with liver diseases including alcoholic hepatitis, noncirrhotic and cirrhotic primary biliary cholangitis.29, 30 To further explore the signalling of intestinal BAs in CHB, we analysed the ratio of faecal DCA/CDCA, which represent the potentials of BAs in activation of intestinal FXR.22, 23 The decreased DCA/CDCA ratio is in accordance with elevated serum FGF19. The gene discussed is NR1H4; the disease is liver disorder.